IGA Glomerulonephritis Clinical Trial
OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of
complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII
contribute to the pathogenesis of IgA glomerulonephritis (IgA-N).
II. Compare genetic anomalies of these key components in immune complex processing and
clearance between juvenile vs adult onset IgA-N vs normal controls.
PROTOCOL OUTLINE:
Participants undergo qualitative genetic analysis of complement-related proteins. Studies
include: genomic re-arrangement of 4-gene unit, C4 DNA sequence and RNA expression, type-1
complement receptor DNA sequence, Fc-gamma receptor IIIA isoform analysis, classical and
alternative complement activation pathway assays, plasma C4 and C4d protein levels, and
immunoglobulin patterns in glomerular deposits.
;
Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004448 -
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
|
Phase 2 | |
| Completed |
NCT01560052 -
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
|
N/A | |
| Completed |
NCT00006137 -
Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
|
N/A | |
| Completed |
NCT02527902 -
Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy
|
N/A | |
| Completed |
NCT01115426 -
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
|
Phase 4 |